



LICENSED
for the treatment of
Active Microscopic Colitis¹




CORTIMENT[®]
budesonide MMX


9 mg tablet once-daily
for up to 8 weeks

CORTIMENT – ONE TREATMENT; TWO COLITIS INDICATIONS¹

- ACTIVE MICROSCOPIC COLITIS
- MILD TO MODERATE ULCERATIVE COLITIS FLARES WHEN 5-ASA IS INSUFFICIENT



EUROPEAN MICROSCOPIC COLITIS TREATMENT GUIDELINES RECOMMEND BUDESONIDE 9 MG/DAY FOR 6 TO 8 WEEKS²



CORTIMENT DOES NOT REQUIRE DOSE TAPERING¹

MICROSCOPIC COLITIS OCCURS THROUGHOUT THE **ENTIRE COLON**⁴

A retrospective review of 84 cases of Microscopic Colitis diagnosed at colonoscopy from 2001 to 2013 was performed by Chapman *et al.* (2014). Only colonoscopies with both right- and left-sided colonic biopsies were included:⁴




90.5% of patients had features of Microscopic Colitis on both the right- and the left-sided biopsies



8.3% of patients had features of Microscopic Colitis on the right side only, and 1.2% on the left side only

96% OF CORTIMENT IS DELIVERED THROUGHOUT THE ENTIRE COLON⁵



CORTIMENT; A SIMPLE DOSAGE REGIMEN:¹



- 1 x 9 mg oral tablet once-daily
- For up to 8 weeks
- No requirement to dose taper
- Taken with or without food

CORTIMENT is to be stored below 30°C and has a shelf life of 3 years.¹



CORTIMENT HAS A **LOW PILL BURDEN** COMPARED TO THE OTHER WIDELY USED BUDESONIDES^{1,6,7}

	CORTIMENT 9 mg tablet	Budenofalk® 3 mg capsule*	Entocort® 3 mg capsule
Price per day ⁸	£2.50	£2.25	£2.25
Price per course ⁸	£140.00	£126.08	£126.08
Pill burden per course ^{1,6,7}	56 tablets	168 capsules	168 capsules



*3 mg capsules constituent 97% of Budenofalk's total oral prescribing over a 12-month period⁹

CORTIMENT – ONE TREATMENT; TWO COLITIS INDICATIONS¹

- **MMX technology** enables targeted release of budesonide throughout the entire colon^{1,5,11–13}
- European Microscopic Colitis guidelines **recommend budesonide as 1st line treatment** for Active Microscopic Colitis²
- **>90%** of Microscopic Colitis patients have **right- and left-sided disease**⁴
- **96% of CORTIMENT** is delivered throughout the entire colon⁵

There are 2 ways a HCP can write/recommend CORTIMENT:

CORTIMENT

(9 mg)

Prolonged release
tablets OD

OR

Budesonide

MMX (9 mg)

Prolonged release
tablets OD



Use this QR code to
access the UK Ferring
Hub to find out more

Prescribing Information: Cortiment® 9 mg, prolonged release tablets. **Please consult the full Summary of Product Characteristics before prescribing. Name of Product(s):** Cortiment® 9 mg, prolonged release tablets **Composition:** One tablet contains 9 mg of budesonide. **Indication:** Induction of remission in patients with mild to moderate active Ulcerative Colitis where 5-ASA treatment is not sufficient and induction of remission in patients with active Microscopic Colitis **Dosage: Adults:** The recommended daily dose for induction of remission for both Ulcerative and Microscopic Colitis is one 9 mg tablet in the morning, for up to 8 weeks. When treatment is discontinued, it may be useful to gradually reduce the dose. **Children:** No data are available, therefore the use in paediatric population is not recommended until further data become available. **Contraindications:** Hypersensitivity to the active substance, soya oil, peanut oil or to any of the excipients of the product. **Special Warnings and Precautions:** Caution is recommended in patients with infections, hypertension, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma or cataracts or with a family history of diabetes or glaucoma or with any other condition where the use of glucocorticoids may have unwanted effects. Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare condition diseases such as Central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids. Reduced liver function may affect the elimination of glucocorticoids including budesonide, causing higher systemic exposure. Treatment with Cortiment tablets

results in lower systemic steroid levels than conventional oral glucocorticoid therapy. As corticosteroids are known to have immunological effects the co-administration of Cortiment tablets is likely to reduce the immune response to vaccines. Concomitant administration of ketoconazole or other potent CYP3A4 inhibitors should be avoided. **Pregnancy:** Cortiment should only be used during pregnancy if the potential benefit justifies the potential risk to the foetus. **Side effects:** For the full list of side effects please consult the Summary of Product Characteristics. **Common:** nausea, abdominal pain upper, abdominal distension, abdominal pain, dry mouth, dyspepsia, headache, insomnia, acne, fatigue, myalgia, blood cortisol decreased. **Uncommon:** Flatulence, dizziness, mood altered, oedema peripheral, back pain, muscle spasms, influenza, leukocytosis. **Nature and Contents of Container:** The tablets are packaged in blister packs with aluminium push through foil, contained in a cardboard carton. **Marketing Authorisation Number:** Tablets 9 mg: 03194/0113 **Marketing Authorisation Holder:** Ferring Pharmaceuticals Ltd., Drayton Hall, Church Road, West Drayton, UB7 7PS, United Kingdom. **Legal Category:** POM. **Basic NHS Price:** £75.00 for 30 x 9 mg tablets. **Date of Preparation of Prescribing Information:** January 2021. Cortiment is a registered trademark. UK-COR-2100001:January 2021.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Ferring Pharmaceuticals Ltd. Tel: 0800 111 4126. Email: medical.uk@ferring.com

1. Cortiment 9 mg Summary of Product Characteristics. 2. Miehke S, *et al. United European Gastroenterol J.* 2020;0(0):1–28. 3. Münch A, *et al. Frontline Gastroenterology.* 2020;11:228–234. 4. Chapman T, *et al. Gut.* 2014;63:A130. 5. Brunner M, *et al. Br J Clin Pharmacol.* 2006;61(1):31–38. 6. Budenofalk 3 mg Gastro-resistant Capsules Summary of Product Characteristics. 7. Entocort CR 3 mg Capsules Summary of Product Characteristics. 8. MIMS 2021. 9. IMS Annual Retail Prescription Data 2020. 10. Budenofalk 9 mg Gastro-resistant Granules Summary of Product Characteristics. 11. Travis SPL, *et al. Gut.* 2014;63:433–441. 12. Fiorino G, *et al. Curr Med Chem.* 2010;17(17):1851– 857. 13. Sandborn JW, *et al. Gastroenterology.* 2012;143:1218–1226.